Biodesix to Participate in Three Investor Conferences in November

BDSX 10.29.2024

Full Press ReleaseSEC FilingsOur BDSX Tweets

About Gravity Analytica

Recent News

  • 01.10.2025 - Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)
  • 01.07.2025 - Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study
  • 11.21.2024 - Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum

Recent Filings

  • 01.10.2025 - EX-99.1 EX-99.1
  • 01.10.2025 - 8-K Current report
  • 11.22.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version

LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) --Biodesix, Inc.(Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences:

Craig-Hallum 15thAnnual Alpha Select Conference1x1 MeetingsDate: Tuesday, November 19, 2024Location: New York, NY

Wolfe Research Healthcare Conference 20241x1 MeetingsDate: Wednesday, November 20, 2024Location: New York, NY

Canaccord Genuity Medtech, Diagnostics and Digital Health & Services ForumPresentation and 1x1 MeetingsPresentation Date and Time: Thursday, November 21, 2024 at 1:00 PM ETLocation: New York, NY

The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website atbiodesix.com.

About Biodesix

Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood-based IQLungTM test portfolio for lung cancer patients integrates the GeneStrat® targeted ddPCRTM test, the GeneStrat NGS® test, and the VeriStrat® test to support treatment decisions across all stages of lung cancer and expedite personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visitbiodesix.com.

Note: Biodesix, Nodify Lung, IQLung, GeneStrat, GeneStrat NGS, VeriStrat, Nodify XL2 and Nodify CDT are trademarks or registered trademarks of Biodesix, Inc. ddPCR is a trademark of Bio-Rad Laboratories, Inc.

Contacts:

Media:Natalie St. DenisNatalie.StDenis@biodesix.com1-720-925-9285

Investors:Chris Brinzeychris.brinzey@westwicke.com1-339-970-2843

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com